JMET Results are out, what is yours?

January 5, 2009

JMET results are out now. Last year JMET ranks were given in 4000’s , However, for a general category student, any rank beyond 1750 means your IIT MBA dream is over. However, This year OBC quota is being implemented at the IIT’s. That means a 54% increase in IIT MBA intake. So, if your rank is less than 2500, congratulations because you might get that IIT MBA call. One more major trend that is observed by MIS team, is JMET have announced the ranks upto 8000!! which is most unlikely with the JMET’s reputation. We are aware that JMET site is facing too much load so for your use and ease you can check your JMET results here.

Enter your JMET 2009 Registration Number :-
 

Hope this JMET leads you to calls of coveted IITs.

Pour in with your comments, we are happy to know your results
Regards,
Team MIS

 

 

Better than Cure

December 30, 2008

Healthy living switches off genes that promote cancer

That a healthy way of life can prevent cancer is well known. It is also becoming clear living can help those who already have tumours to survive, and may even prevent the disease from coming back. A number of studies have shown these effects in breast cancer and colon cancer. But how they work at a molecualr level remains a mystery.

For examply, prostate cancer, it is slow-growing. When such a cancer has been diagnosed early, doing nothing is a reasonable alternative to the trauma of surgery, radiation or hormone therapy. Dr Ornish of the University of California, San Francisco enrolled 30 such early-stage patients into a programme of “comprehensive lifestyle changes”. These included a low-fat, whole-food, plant-based diet, stress management, moderate exercise and plenty of “psychosocial group support”. Patients’ prostates were sampled at the start of the study, and then three months later to see what had changed.

For a gene to do its work, it has to be transcribed into a molecular messenger. This messenger, a molecule of a substance called RNA, carries instructions to the protein-making parts of a cell, telling them what to make. The more RNA messengers that have been transcribed from a gene, the more active that gene is assumed to be. Count the shifting number of messengers, then, and you can see the effects on the genes of a course of treatment. And that, using so-called gene-chip technology, is what Dr Ornish did.

[Read more]

Making of a CEO

December 29, 2008

In “Defining the Duties of the American CEO”, belived to be his last article, Peter F. Drucker says, “The CEO is an American invention - de-signed first by Alexander Hamilton in the Constitution in the earliest years of the Republic, and then transfered to the private sector in the form of Hamilton’s own Bank of New York and of the Second Bank of the United States in Philadelphia. There is no real counterpart to the CEO in the management and organization of any other country. The German ‘Sprecher des Vorstands,’ the French ‘Administrateur Delegue,’ the British ‘Chairman’, or the Japanese ‘President’ are all quite different in their powers and the limitations thereon”.

Whatever may be the nomenclature, every CEO is hired to deliver results-be it for a company, an NGO, a government, or a project. “CEOs have the ultimate responsibility for the work of everybody else in their institution. But they also have work of their own. In any organization, regardlesss of its mission, the CEO is the link between the Inside, i.e. the organization, and the Outside - society, the economy, technology, markets, customers, the media and public option. Inside, there are only costs. Results are only on the outside,” observed the legendary management guru.

[Read more]

Piramal Health signed a deal to buy US based Minrad for $40 mn

December 23, 2008

Reuters:

Livemint:

Pharma company Piramal Healthcare Ltd said on Tuesday that it has signed a deal to buy US based inhalation anaesthetics maker Minrad International Inc for about US $40 million in cash and debt.

Under the terms, Minrad shareholders will get 12 cents a share in cash, a 100% premium to the stock’s on Monday closing price on the American Stock Exchange (Amex).
Piramal will also buy Minrad’s senior secured convertible notes, the company said in a statement to the stock exchange.
“The offer to Minrad is consistent with our commitment to build a serious global presence in critical care,” chairman Ajay Piramal said in the note.
With the acquisition, Piramal will gain access to the intellectual property for making inhalation anaesthetics and will be able to immediately break into the US pharmaceutical market for the country’s top-selling inhalation anaesthetic, sevoflurane.
The deal is expected to close in the first quarter of 2009 subject to Minrad shareholders approval and will add to Piramal’s earnings for the year to March 2010, the company said.
This year, the company has already acquired German PlasmaSelect AG’s blood expansion products, two brands from the India-based Khandelwal Labs, and bought out Bangalore-based Healthline Pvt Ltd’s drug business.
Piramal shares are trading 2.9% lower at Rs236.05 on very low volumes in a weak Mumbai market, while Minrad ended on Monday 14.3% lower at 6 cents on the Amex.

Next Page »

eXTReMe Tracker